Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News


Chimeric Therapeutics - Security Class Suspension from Quotation CHMO


The options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in CHM’s Prospectus, announced to the market on 21 February 2022. The options are expected to be quoted on a normal settlement basis on Monday, 28 March 2022.

The suspension only applies to the CHM’s options (ASX: CHMO), and does not apply to any other quoted securities of CHM. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.